<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967656/" ref="ordinalpos=748&amp;ncbi_uid=2560781&amp;link_uid=PMC2967656" image-link="/pmc/articles/PMC2967656/figure/F1/" class="imagepopup">Figure 1. An overview of some ghrelin and GHS-R1a down-stream <span class="highlight" style="background-color:">signaling</span> pathways.  From: Ghrelin receptor <span class="highlight" style="background-color:">signaling</span>: a promising therapeutic target for metabolic syndrome and cognitive dysfunction. </a></div><br /><div class="p4l_captionBody">These signaling pathways include the dominant growth hormone secretagogue-related PLC/PKC/IP3 pathway, hypothalamic ghrelin activation of NPY-containing neurons and inhibition of POMC neurons, and ghrelin augmentation of dopamine signaling, involving GHS-R1a/D1R heterodimerization, leading to a synergistic activation of AC2 via Gαs (D1Rcoupling) and βγ-subunits derived from Gαi (GHS-R1a coupling). DAG = diacylglycerol, IP3 =Inositol(1,4,5)triphosphate, POMC = pro-opiomelanocortin, D1R = dopamine receptor 1, AC2 = adenylyl cyclase-2</div></div>